Beta Bionics (NASDAQ:BBNX) CFO Stephen Feider Sells 1,427 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 1,427 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $29.34, for a total value of $41,868.18. Following the transaction, the chief financial officer owned 42,614 shares in the company, valued at $1,250,294.76. This represents a 3.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Stephen Feider also recently made the following trade(s):

• On Friday, October 3rd, Stephen Feider sold 4,982 shares of Beta Bionics stock. The stock was sold at an average price of $21.69, for a total value of $108,059.58.
• On Wednesday, October 1st, Stephen Feider sold 15,018 shares of Beta Bionics stock. The stock was sold at an average price of $20.76, for a total value of $311,773.68.
• On Friday, September 5th, Stephen Feider sold 100 shares of Beta Bionics stock. The shares were sold at an average price of $21.00, for a total value of $2,100.00.

Beta Bionics Price Performance

Shares of NASDAQ BBNX traded down $0.44 during trading hours on Friday, reaching $29.56. The stock had a trading volume of 78,002 shares, compared to its average volume of 609,718. The company has a market cap of $1.30 billion and a price-to-earnings ratio of -6.76. Beta Bionics, Inc. has a twelve month low of $8.89 and a twelve month high of $32.71. The business’s fifty day moving average is $25.15 and its two-hundred day moving average is $20.01.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings results on Tuesday, October 28th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%. The firm had revenue of $27.25 million for the quarter, compared to the consensus estimate of $23.92 million.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Piper Sandler reissued an “overweight” rating and issued a $32.00 target price (up previously from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. The Goldman Sachs Group lifted their price objective on Beta Bionics from $26.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Truist Financial reiterated a “buy” rating and issued a $32.00 price objective (up from $28.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. Robert W. Baird set a $23.00 target price on Beta Bionics in a report on Wednesday, October 29th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $31.00 price target (up previously from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.22.

Institutional Trading of Beta Bionics

Large investors have recently added to or reduced their stakes in the company. GPS Wealth Strategies Group LLC raised its stake in shares of Beta Bionics by 45.0% in the third quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after acquiring an additional 450 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Beta Bionics by 203.6% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after acquiring an additional 1,594 shares during the last quarter. Verition Fund Management LLC increased its holdings in Beta Bionics by 4.0% during the 3rd quarter. Verition Fund Management LLC now owns 47,299 shares of the company’s stock valued at $940,000 after purchasing an additional 1,823 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in Beta Bionics by 139.1% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock valued at $64,000 after purchasing an additional 1,863 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in Beta Bionics by 10.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,558 shares of the company’s stock valued at $343,000 after purchasing an additional 2,205 shares during the last quarter.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.